The present disclosure relates to pharmaceutical compositions with increased skin permeability for treating ear disease in mammals. Disclosed pharmaceutical compositions are prepared as topical gels or as transdermal gels. The pharmaceutical compositions reduce ear inflammation and irritation produced by ear diseases or injuries (e.g., cauliflower ear, chronic otitis, and the like). The pharmaceutical compositions include a synergistic combination of pracaxi oil and seje oil. Additionally, the pharmaceutical compositions include phosphatidylcholine as a permeation enhancer. The combination of aforementioned natural components exhibits enhanced healing properties, thereby providing organic acids with antioxidant, antibacterial, and antifungal properties. The synergistic combination of pracaxi and seje oil increases the skin permeability to active pharmaceutical ingredients (APIs), thereby passing through the stratum corneum and reaching the target area; therefore, the dosage and time of treatment is significantly reduced.

The invention provides a dermatological kit comprising a first container comprising a first composition and a second container comprising a second composition, different from the first composition, wherein the first composition comprises trichloro-acetic acid and a hibiscus acid, wherein the second composition comprises a material of Mauritia flexuosa origin and a hibiscus acid, and wherein the second composition has a sun protection factor (SPF) of at least 15.

The invention provides a dermatological kit comprising a first container comprising a first composition and a second container comprising a second composition, different from the first composition, wherein the first composition comprises trichloro-acetic acid and a hibiscus acid, wherein the second composition comprises a material of Mauritia flexuosa origin and a hibiscus acid, and wherein the second composition has a sun protection factor (SPF) of at least 15.

The invention provides a dermatological kit comprising a first container comprising a first composition and a second container comprising a second composition, different from the first composition, wherein the first composition comprises trichloro-acetic acid and a hibiscus acid, wherein the second composition comprises a material of Mauritia flexuosa origin and a hibiscus acid, and wherein the second composition has a sun protection factor (SPF) of at least 15.

Provided herein are compositions and methods for preparing foods and beverages that contain additives, such as nutraceuticals, pharmaceuticals, and supplements, such as essential fatty acids, including omega-3 fatty acids, omega-6 fatty acids, conjugated fatty acids, and other fatty acids; phytochemicals, including phytosterols; other oils; and coenzymes, including Coenzyme Q10, and other oil-based additives.

Provided herein are compositions and methods for preparing foods and beverages that contain additives, such as nutraceuticals, pharmaceuticals, and supplements, such as essential fatty acids, including omega-3 fatty acids, omega-6 fatty acids, conjugated fatty acids, and other fatty acids; phytochemicals, including phytosterols; other oils; and coenzymes, including Coenzyme Q10, and other oil-based additives.

Provided herein are compositions and methods for preparing foods and beverages that contain additives, such as nutraceuticals, pharmaceuticals, and supplements, such as essential fatty acids, including omega-3 fatty acids, omega-6 fatty acids, conjugated fatty acids, and other fatty acids; phytochemicals, including phytosterols; other oils; and coenzymes, including Coenzyme Q10, and other oil-based additives.

In various implementations, berberine metabolites, such as dihydroberberine and/or tetrahydroberberine, may be administered to manage blood glucose levels, increase ketone levels (e.g., blood concentration of ketones), and/or for therapeutic purposes in humans. The administration of a pharmaceutically effective amount of berberine metabolites, such as dihydroberberine, may reduce fasting blood glucose levels, improve glucose tolerance, and/or improve blood ketone response. In some implementations, berberine metabolites may be administered with one or more other compounds.

In various implementations, berberine metabolites, such as dihydroberberine and/or tetrahydroberberine, may be administered to manage blood glucose levels, increase ketone levels (e.g., blood concentration of ketones), and/or for therapeutic purposes in humans. The administration of a pharmaceutically effective amount of berberine metabolites, such as dihydroberberine, may reduce fasting blood glucose levels, improve glucose tolerance, and/or improve blood ketone response. In some implementations, berberine metabolites may be administered with one or more other compounds.

The present invention relates to a composition for the treatment of colon disorder comprising oil palm polyphenolics (OPP) and fibres extracted from the vegetation liquor generated during the milling and extraction of oil from the oil palm fruit administered to a patient in an effective concentration of 50 mg gallic acid equivalents (GAE). The present invention further relates to a method of treatment and prevention of colon disorders and maintenance of gut health.